Journal articles
Cooke GS; Pett S; McCabe L; Jones C; Gilson R; Verma S; Ryder SD; Collier JD; Barclay ST; Ala A; Bhagani S; Nelson M; Ch'Ng C; Stone B; Wiselka M; Forton D; McPherson S; Halford R; Nguyen D; Smith D; Ansari A; Dennis E; Hudson F; Barnes EJ; Walker AS, 2021, 'Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C.', Wellcome Open Res, 6, pp. 93, http://dx.doi.org/10.12688/wellcomeopenres.16594.2
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP, 2021, 'The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.', Lancet Glob Health, 9, pp. e620 - e627, http://dx.doi.org/10.1016/S2214-109X(21)00025-5
Burns JE; Stöhr W; Kinloch-De Loes S; Fox J; Clarke A; Nelson M; Thornhill J; Babiker A; Frater J; Pett SL; Fidler S, 2021, 'Tolerability of four-drug antiretroviral combination therapy in primary HIV-1 infection.', HIV Med, 22, pp. 770 - 774, http://dx.doi.org/10.1111/hiv.13118
Cooke GS; Pett S; McCabe L; Jones C; Gilson R; Verma S; Ryder SD; Collier JD; Barclay ST; Ala A; Bhagani S; Nelson M; Ch’Ng CL; Stone B; Wiselka M; Forton D; McPherson S; Halford R; Nguyen D; Smith D; Ansari MA; Ainscough H; Dennis E; Hudson F; Barnes EJ; Walker AS, 2021, 'Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT', Efficacy and Mechanism Evaluation, 8, pp. 1 - 90, http://dx.doi.org/10.3310/eme08170
Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; De Castilla DL; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC; Rouphael NG; Traenkner JJ; Cantos VD; Alaaeddine G; Grossberg R; Riska PF; Torres-Soto M; Jilg N; Wald A; Crouch PB; Jang H; Billings J; Noren B; Van Winkle JW; Riedo FX; Wang JP; Wessolossky M; Eckhardt B; Neumann HJ; Grein J; Sutterwala F; Amin AN; Javeri H; Vu T; Mateu L; Benson CA; Ali F; Tebas P; Torgersen J; Gioukari V; Ong SWX; Mikami A; Malin JJ; Koehler P; Larson L; Hewlett A; Thomsen I; Rice TW; Taiwo B; Krueger K; Cohen SH; Thompson GR; Wolfe C; Walter EB; Frank M; Young H; Falsey AR; Branche AR; Goepfert P; Erdmann N; Yang OO; Ahn J; Goodman A; Merrick B; Novak RM; Wendrow A; Arguinchona H; Arguinchona C; George SL; Tennant J, 2020, 'Remdesivir for the treatment of COVID-19 — Final report', New England Journal of Medicine, 383, pp. 1813 - 1826, http://dx.doi.org/10.1056/NEJMoa2007764
Noor NM; Pett SL; Esmail H; Crook AM; Vale CL; Sydes MR; Parmar MKB, 2020, 'Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings', F1000Research, 9, pp. 1109 - 1109, http://dx.doi.org/10.12688/f1000research.26253.1
McCabe L; White IR; Chau NVV; Barnes E; Pett SL; Cooke GS; Walker AS; SEARCH investigators , 2020, 'The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.', Trials, 21, pp. 413, http://dx.doi.org/10.1186/s13063-020-04350-x
Fidler S; Stöhr W; Pace M; Dorrell L; Lever A; Pett S; Kinloch-de Loes S; Fox J; Clarke A; Nelson M; Thornhill J; Khan M; Fun A; Bandara M; Kelly D; Kopycinski J; Hanke T; Yang H; Bennett R; Johnson M; Howell B; Barnard R; Wu G; Kaye S; Wills M; Babiker A; Frater J; RIVER trial study group , 2020, 'Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.', Lancet, 395, pp. 888 - 898, http://dx.doi.org/10.1016/S0140-6736(19)32990-3
Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M; Mugyenyi P; Kityo C; Wavamunno P; Nambi E; Ocitti P; Ndigendawani M; Kabahenda S; Kemigisa M; Acen J; Olebo D; Mpamize G; Amone A; Okweny D; Mbonye A; Nambaziira F; Rweyora A; Kangah M; Kabaswahili V; Abach J; Abongomera G; Omongin J; Aciro I; Philliam A; Arach B; Ocung E; Amone G; Miles P; Adong C; Tumsuiime C; Kidega P; Otto B; Apio F; Baleeta K; Mukuye A; Abwola M; Ssennono F; Baliruno D; Tuhirwe S; Namisi R; Kigongo F; Kikyonkyo D; Mushahara F; Tusiime J; Musiime A; Nankya A; Atwongyeire D; Sirikye S; Mula S; Noowe N; Lugemwa A; Kasozi M; Mwebe S; Atwine L; Senkindu T; Natuhurira T; Katemba C; Ninsiima E; Acaku M; Kyomuhangi J; Ankunda R; Tukwasibwe D; Ayesiga L; Hakim J; Nathoo K; Reid A; Chidziva E; Mhute T; Tinago GC; Bhiri J; Mudzingwa S; Phiri M; Steamer J; Nhema R; Warambwa C; Musoro G; Mutsai S; Nemasango B; Moyo C; Chitongo S; Rashirai K; Vhembo S; Mlambo B; Nkomani S; Ndemera B; Willard M; Berejena C; Musodza Y; Matiza P, 2020, 'The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa', Journal of the International AIDS Society, 23, http://dx.doi.org/10.1002/jia2.25469
Dwyer DE; Lynfield R; Losso MH; Davey RT; Cozzi-Lepri A; Wentworth D; Uyeki TM; Gordin F; Angus B; Qvist T; Emery S; Lundgren J; Neaton JD, 2020, 'Comparison of the outcomes of individuals with medically attended influenza a and b virus infections enrolled in 2 international cohort studies over a 6-year period: 2009-2015', Open Forum Infectious Diseases, 4, http://dx.doi.org/10.1093/ofid/ofx212
Burns JE; Stirrup OT; Dunn D; Runcie-Unger I; Milinkovic A; Candfield S; Lukha H; Severn A; Waters L; Edwards S; Gilson R; Pett SL, 2020, 'No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV', AIDS, 34, pp. 109 - 114, http://dx.doi.org/10.1097/QAD.0000000000002379
Noor NM; Pett SL; Esmail H; Crook AM; Vale CL; Sydes MR; Parmar MKB, 2020, 'Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings.', F1000Res, 9, pp. 1109, http://dx.doi.org/10.12688/f1000research.26253.2
Varatharaj A; Pollak TA; Nicholson TR; Coles JP; Benjamin LA; Carson A; Thomas RH; Michael BD; study authors , 2020, 'Characterising neuropsychiatric disorders in patients with COVID-19 - Authors' reply.', Lancet Psychiatry, 7, pp. 934 - 935, http://dx.doi.org/10.1016/S2215-0366(20)30420-X
Ellul M; Varatharaj A; Nicholson TR; Pollak TA; Thomas N; Easton A; Zandi MS; Manji H; Solomon T; Carson A; Turner MR; Kneen R; Galea I; Pett S; Thomas RH; Michael BD; CoroNerve Steering Committee , 2020, 'Defining causality in COVID-19 and neurological disorders.', J Neurol Neurosurg Psychiatry, 91, pp. 811 - 812, http://dx.doi.org/10.1136/jnnp-2020-323667
Varatharaj A; Thomas N; Ellul MA; Davies NWS; Pollak TA; Tenorio EL; Sultan M; Easton A; Breen G; Zandi M; Coles JP; Manji H; Al-Shahi Salman R; Menon DK; Nicholson TR; Benjamin LA; Carson A; Smith C; Turner MR; Solomon T; Kneen R; Pett SL; Galea I; Thomas RH; Michael BD; CoroNerve Study Group , 2020, 'Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study.', Lancet Psychiatry, 7, pp. 875 - 882, http://dx.doi.org/10.1016/S2215-0366(20)30287-X
Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD; Butts J; Denning E; DuChene A; Krum E; Harrison M; Meger S; Peterson R; Quan K; Shaughnessy M; Thompson G; Vock D; Metcalf J; Dewar R; Rehman T; Natarajan V; McConnell R; Flowers E; Smith K; Hoover M; Coyle EM; Munroe D; Aagaard B; Pearson M; Cursley A; Webb H; Hudson F; Russell C; Sy A; Purvis C; Jackson B; Collaco-Moraes Y; Carey D; Robson R; Sánchez A; Finley E; Conwell D; Losso MH; Gambardella L; Abela C; Lopez P; Alonso H; Touloumi G; Gioukari V; Anagnostou O; Avihingsanon A; Pussadee K; Ubolyam S; Omotosho B; Solórzano C; Petersen T; Vysyaraju K; Rizza SA; Whitaker JA; Nahra R; Baxter J; Coburn P; Gardner EM; Scott JA; Faber L; Pastor E; Makohon L; MacArthur RA; Hillman LM; Farrough MJ; Polenakovik HM; Clark LA; Colon RJ; Kunisaki KM; DeConcini M; Johnson SA; Wolfe CR; Mkumba L; Carbonneau JY; Morris A; Fitzpatrick ME; Kessinger CJ; Salata RA; Arters KA; Tasi CM; Panos RJ; Lach LA, 2019, 'Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial', The Lancet Respiratory Medicine, 7, pp. 951 - 963, http://dx.doi.org/10.1016/S2213-2600(19)30253-X
Peterson I; Ntsui N; Jambo K; Kelly C; Huwa J; Afran L; Tatuene JK; Pett S; Romain Henrion MY; Van Oosterhout J; Heyderman RS; Mwandumba H; Benjamin LA; Angus B; Connor M; Dwivedi R; Haddow L; Heikinheimo-Connell T; Joekes E; Kandoole V; Nyrienda M; Malisita K; Mallewa J; Soliman EZ; Solomon T, 2019, 'Evaluating the reactivation of herpesviruses and inflammation as cardiovascular and cerebrovascular risk factors in antiretroviral therapy initiators in an African HIV-infected population (RHICCA): A protocol for a longitudinal cohort study', BMJ Open, 9, http://dx.doi.org/10.1136/bmjopen-2018-025576
Castillo-Mancilla JR; Phillips AN; Neaton JD; Neuhaus J; Sharma S; Baker JV; Collins S; Mannheimer S; Pett S; Touzeau-Römer V; Polizzotto MN; Lundgren JD; Gardner EM, 2019, 'Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study', Journal of the International AIDS Society, 22, http://dx.doi.org/10.1002/jia2.25297
Gatell JM; Assoumou L; Moyle G; Waters L; Johnson M; Domingo P; Fox J; Martinez E; Stellbrink H-J; Guaraldi G; Masia M; Gompels M; De Wit S; Florence E; Esser S; Raffi F; Stephan C; Rockstroh J; Giacomelli A; Vera J; Bernardino JI; Winston A; Saumoy M; Gras J; Katlama C; Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group , 2019, 'Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.', Clin Infect Dis, 68, pp. 597 - 606, http://dx.doi.org/10.1093/cid/ciy505
Polizzotto M; Van Bockel D; Law C; Roberts J; Buckland G; Just S; Comben S; Hillman R; Gilson R; Pett S; Poynten M; Law M; Kelleher A; Emery S, 2019, 'Clearance of HPV Anal Premalignant Lesions and Modulation of Systemic Immune Responses to HPV Oncogenes with Low Dose Pomalidomide', Annals of Oncology, 30, pp. xi35 - xi35, http://dx.doi.org/10.1093/annonc/mdz451.005
Alagaratnam J; Stohr W; Toombes J; Zetterberg H; Pett S; Nelson M; Kinloch S; Clarke A; Nwokolo N; Johnson M; Fox J; Hanke T; Kopycinski J; Dorrell L; Babiker A; Frater J; Winston A; Fidler S, 2019, 'No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial', Journal of Virus Eradication, 5, pp. 22 - 23, http://dx.doi.org/10.1016/s2055-6640(20)31066-9
Kityo C; Szubert AJ; Siika A; Heyderman R; Bwakura-Dangarembizi M; Lugemwa A; Mwaringa S; Griffiths A; Nkanya I; Kabahenda S; Wachira S; Musoro G; Rajapakse C; Etyang T; Abach J; Spyer MJ; Wavamunno P; Nyondo-Mipando L; Chidziva E; Nathoo K; Klein N; Hakim J; Gibb DM; Walker AS; Pett SL, 2018, 'Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial', PLoS Medicine, 15, http://dx.doi.org/10.1371/journal.pmed.1002706
Vanderven HA; Wragg K; Ana-Sosa-Batiz F; Kristensen AB; Jegaskanda S; Wheatley AK; Wentworth D; Wines BD; Hogarth PM; Rockman S; Kent SJ; INSIGHT FLU005 Pilot Study Writing Group , 2018, 'Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection.', J Infect Dis, 218, pp. 1383 - 1393, http://dx.doi.org/10.1093/infdis/jiy328
Simonsen L; Higgs E; Taylor RJ; Wentworth D; Cozzi-Lepri A; Pett S; Dwyer DE; Davey R; Lynfield R; Losso M; Morales K; Glesby MJ; Weckx J; Carey D; Lane C; Lundgren J; Emery S, 2018, 'Using clinical research networks to assess severity of an emerging influenza pandemic', Clinical Infectious Diseases, 67, pp. 341 - 349, http://dx.doi.org/10.1093/cid/ciy088
Mallewa J; Szubert AJ; Mugyenyi P; Chidziva E; Thomason MJ; Chepkorir P; Abongomera G; Baleeta K; Etyang A; Warambwa C; Melly B; Mudzingwa S; Kelly C; Agutu C; Wilkes H; Nkomani S; Musiime V; Lugemwa A; Pett SL; Bwakura-Dangarembizi M; Prendergast AJ; Gibb DM; Walker AS; Berkley JA; Kityo C; Wavamunno P; Nambi E; Ocitti P; Ndigendawani M; Kabahenda S; Kemigisa M; Acen J; Olebo DF; Mpamize G; Amone A; Okweny D; Mbonye A; Nambaziira F; Rweyora A; Kangah M; Kabaswahili B; Abach J; Omongin J; Aciro I; Philliam A; Arach B; Ocung E; Amone G; Miles P; Adong C; Tumsuiime C; Kidega P; Otto B; Apio F; Mukuye A; Abwola M; Ssennono F; Baliruno D; Tuhirwe S; Namisi R; Kigongo F; Kikyonkyo D; Mushahara F; Tusiime J; Musiime A; Nankya A; Atwongyeire D; Sirikye S; Myalo S; Noowe N; Kasozi M; Mwebe S; Atwine L; Senkindu T; Natuhurira I; Katemba C; Ninsiima E; Acaku M; Kyomuhangi J; Ankunda R; Tukwasibwe D; Ayesiga L; Hakim J; Nathoo K; Reid A; Mhute T; Tinago G; Bhiri J; Phiri M; Steamer J; Nhema R; Musoro G; Mutsai S; Nemasango B; Moyo C; Chitongo S; Rashirai K; Vhembo S; Mlambo B; Ndemera B, 2018, 'Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial', The Lancet HIV, 5, pp. e231 - e240, http://dx.doi.org/10.1016/S2352-3018(18)30038-9
Post FA; Szubert AJ; Prendergast AJ; Johnston V; Lyall H; Fitzgerald F; Musiime V; Musoro G; Chepkorir P; Agutu C; Mallewa J; Rajapakse C; Wilkes H; Hakim J; Mugyenyi P; Sarah Walker A; Gibb DM; Pett SL; Kityo C; Wavamunno P; Nambi E; Ocitti P; Ndigendawani M; Portal F; Kabahenda S; Kemigisa M; Acen J; Olebo D; Mpamize G; Amone A; Okweny D; Mbonye A; Nambaziira F; Rweyora A; Kangah M; Kabaswahili V; Abach J; Abongomera G; Omongin J; Aciro I; Philliam A; Arach B; Ocung E; Amone G; Miles P; Adong C; Tumsuiime C; Kidega P; Otto B; Apio F; Baleeta K; Mukuye A; Abwola M; Ssennono F; Baliruno D; Tuhirwe S; Namisi R; Kigongo F; Kikyonkyo D; Mushahara F; Tusiime J; Musiime A; Nankya A; Atwongyeire D; Sirikye S; Mula S; Noowe N; Lugemwa A; Kasozi M; Mwebe S; Atwine L; Senkindu T; Natuhurira T; Katemba C; Ninsiima E; Acaku M; Kyomuhangi J; Ankunda R; Tukwasibwe D; Ayesiga L; Nathoo K; Bwakura-Dangarembizi M; Reid A; Chidziva E; Mhute T; Tinago GC; Bhiri J; Mudzingwa S; Phiri M; Steamer J; Nhema R; Warambwa C; Mutsai S; Nemasango B; Moyo C; Chitongo S; Rashirai K; Vhembo S; Mlambo B; Nkomani S, 2018, 'Causes and Timing of Mortality and Morbidity among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial', Clinical Infectious Diseases, 66, pp. S132 - S139, http://dx.doi.org/10.1093/cid/cix1141
Siika A; McCabe L; Bwakura-Dangarembizi M; Kityo C; Mallewa J; Berkley J; Maitland K; Griffiths A; Baleeta K; Mudzingwa S; Abach J; Nathoo K; Thomason MJ; Prendergast AJ; Walker AS; Gibb DM; Mugyenyi P; Musiime V; Wavamunno P; Nambi E; Ocitti P; Ndigendawani M; Kemigisa M; Acen J; Olebo D; Mpamize G; Amone A; Okweny D; Mbonye A; Nambaziira F; Rweyora A; Kangah M; Kabaswahili V; Abongomera G; Omongin J; Aciro I; Philliam A; Arach B; Ocung E; Amone G; Miles P; Adong C; Tumsuiime C; Kidega P; Otto B; Apio F; Mukuye A; Abwola M; Ssennono F; Baliruno D; Tuhirwe S; Namisi R; Kigongo F; Kikyonkyo D; Mushahara F; Tusiime J; Musiime A; Nankya A; Atwongyeire D; Sirikye S; Mula S; Noowe N; Lugemwa A; Kasozi M; Mwebe S; Atwine L; Senkindu T; Natuhurira T; Katemba C; Ninsiima E; Acaku M; Kyomuhangi J; Ankunda R; Tukwasibwe D; Ayesiga L; Hakim J; Reid A; Chidziva E; Mhute T; Tinago GC; Bhiri J; Phiri M; Steamer J; Nhema R; Warambwa C; Musoro G; Mutsai S; Nemasango B; Moyo C; Chitongo S; Rashirai K; Vhembo S; Mlambo B; Nkomani S; Ndemera B; Willard M; Berejena C; Musodza Y; Matiza P; Mudenge B, 2018, 'Late Presentation with HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial', Clinical Infectious Diseases, 66, pp. S140 - S146, http://dx.doi.org/10.1093/cid/cix1142
Powers JH; Bacci ED; Leidy NK; Poon JL; Stringer S; Memoli MJ; Han A; Fairchok MP; Coles C; Owens J; Chen WJ; Arnold JC; Danaher PJ; Lalani T; Burgess TH; Millar EV; Ridore M; Hernández A; Rodríguez-Zulueta P; Ortega-Gallegos H; Galindo-Fraga A; Ruiz-Palacios GM; Pett S; Fischer W; Gillor D; Macias LM; DuVal A; Rothman R; Dugas A; Guerrero ML, 2018, 'Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)', PLoS ONE, 13, http://dx.doi.org/10.1371/journal.pone.0194180
Powers JH; Bacci ED; Guerrero ML; Leidy NK; Stringer S; Kim K; Memoli MJ; Han A; Fairchok MP; Chen WJ; Arnold JC; Danaher PJ; Lalani T; Ridoré M; Burgess TH; Millar EV; Hernández A; Rodríguez-Zulueta P; Smolskis MC; Ortega-Gallegos H; Pett S; Fischer W; Gillor D; Macias LM; DuVal A; Rothman R; Dugas A; Ruiz-Palacios GM, 2018, 'Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients', Value in Health, 21, pp. 210 - 218, http://dx.doi.org/10.1016/j.jval.2017.04.014
Castillo-Mancilla JR; Phillips AN; Neaton JD; Neuhaus J; Collins S; Mannheimer S; Pett S; Touzeau-Römer V; Polizzotto MN; Lundgren JD; Gardner EM, 2018, 'Association of Suboptimal Antiretroviral Therapy Adherence with Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofx275
Pett SL; Kunisaki KM; Wentworth D; Griffin TJ; Kalomenidis I; Nahra R; Sanchez RM; Hodgson SW; Ruxrungtham K; Dwyer D; Davey RT; Wendt CH; Lundgren J; Jansson P; Pearson M; Aagaard B; Hudson F; Bennet R; Pacciarini F; Angus B; Paton N; Collaco Moraes Y; Cooper D; Emery S; Courtney-Rogers D; Robson R; Gordin F; Sanchez A; Standridge B; Vjecha M; Moricz A; Delfino M; Belloso W; Losso M; Tillmann K; Touloumi G; Gioukari V; Anagnostou O; La Rosa A; Saenz MJ; Lopez P; Herrero P; Portas B; Kaewon P; Ubolyam S; Brekke K; Campbell M; Denning E; DuChene A; Engen N; George M; Harrison M; Neaton JD; Nelson R; Quan SF; Schultz T; Baxter J; Brown S; Hoover M; Beigel J; Dewar R; Gover E; McConnell R; Metcalf J; Natarajan V; Rehman T; Voell J; Dwyer DE; Kok J; Uyeki T; Munroe D; Paez A; Bertrand M; Temesgen Z; Rizza S; Wolfe C; Carbonneau J; Novak R; Schwarber M; Polenakovik H; Clark L; Patil N; Riska P; Omotosho J; Faber L; Markowitz N; Glesby M; Ham K; Parenti D; Simon G; Coburn P; Freiberg M; Koerbel G; Dharan N; Paez-Quinde M; Gunter J; Beilke M; Lu Z; Gunderson E; Baker J, 2018, 'Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study', Open Forum Infectious Diseases, 5, pp. ofx228, http://dx.doi.org/10.1093/ofid/ofx228
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S; Fisher M; Rockstroh J; Stellbrink J; Merlin K; Yeung J; Fsadni B; Marks K; Suzuki K; Rismanto N; Salomon H; Rubio AE; Chibo D; Birch C; Swenson L; Chan D; Berg T; Obermeier M; Schuelter E; Aragon SS; Luebke N; Coughlan S; Dean J; Iwatani Y; Teran GR; Avila S; Sirivichayakul S; Naphassanant M; Ubolyam S; Kaye S; Land S; Walker S; Haubrich R; DeJesus E; Berthon-Jones N; Espinosa N; Courtney-Vega K; Absar N; Haskelberg H; Robson R; Donaldson A; Guelman D; Gambardella L; Valdovinos M; Arnaiz J; Beleta H; Ramos N; Targa M; Späth B; Boesecke C; Engelhardt A; Perry N; Beckthold B; Drummond F; Lefevre E; Corr S; Grant C; Lupo S; Peroni L; Sanchez M; De Paz Sierra M; Viloria G; Parlante A; Bissio E; Luchetti P; Confalonieri V; Warley E; Vieni I; Vilas C; Zarate A; Mayer G; Elliot J; Hagenauer M; Kelley M; Bloch M; Cooper D, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532
Hakim J; Musiime V; Szubert AJ; Mallewa J; Siika A; Agutu C; Walker S; Pett SL; Bwakura-Dangarembizi M; Lugemwa A; Kaunda S; Karoney M; Musoro G; Kabahenda S; Nathoo K; Maitland K; Griffiths A; Thomason MJ; Kityo C; Mugyenyi P; Prendergast AJ; Walker AS; Gibb DM; REALITY Trial Team , 2017, 'Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.', N Engl J Med, 377, pp. 233 - 245, http://dx.doi.org/10.1056/NEJMoa1615822
Peterson RL; Vock DM; Powers JH; Emery S; Cruz EF; Hunsberger S; Jain MK; Pett S; Neaton JD, 2017, 'Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization', Clinical Trials, 14, pp. 264 - 276, http://dx.doi.org/10.1177/1740774517697919
Kelly ML; Pinto AN; Suan D; Marriott D; Cooper DA; Pett SL, 2017, 'Managing two decades of visceral leishmaniasis and HIV co-infection: A case report that illustrates the urgent research needs in the field', Sexual Health, 14, pp. 286 - 288, http://dx.doi.org/10.1071/SH16036
Fox-Lewis A; Brima N; Muniina P; Grant AD; Edwards SG; Miller RF; Pett SL, 2016, 'Tuberculosis screening in patients with HIV: An audit against UK national guidelines to assess current practice and the effectiveness of an electronic tuberculosis-screening prompt', International Journal of STD and AIDS, 27, pp. 901 - 905, http://dx.doi.org/10.1177/0956462416628355
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S; Cooper D; Tu E; Silk D, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207
Ryder S; Pett S; Cooke GS, 2016, 'Genotype 4 and the global challenge of hepatitis C treatment', The Lancet Gastroenterology and Hepatology, 1, pp. 3 - 4, http://dx.doi.org/10.1016/S2468-1253(16)30006-1
Churchill D; Waters L; Ahmed N; Angus B; Boffito M; Bower M; Dunn D; Edwards S; Emerson C; Fidler S; Fisher M; Horne R; Khoo S; Leen C; Mackie N; Marshall N; Monteiro F; Nelson M; Orkin C; Palfreeman A; Pett S; Phillips A; Post F; Pozniak A; Reeves I; Sabin C; Trevelion R; Walsh J; Wilkins E; Williams I; Winston A, 2016, 'British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.', HIV Med, 17 Suppl 4, pp. s2 - s104, http://dx.doi.org/10.1111/hiv.12426
Powers JH; Bacci ED; Leidy NK; Stringer S; Kim K; Memoli MJ; Han A; Fairchok MP; Chen W; Arnold JC; Danaher PJ; Lalani T; Hansen EA; Ridore M; Burgess TH; Millar EV; Hernández A; Rodríguez-Zulueta P; Ortega-Gallegos H; Galindo-Fraga A; Ruiz-Palacios GM; Pett S; Fischer W; Gillor D; Macias LM; DuVal A; Rothman R; Dugas A; Guerrero ML, 2016, 'Evaluation of the Performance Properties of the Influenza Patient-Reported Outcomes Instrument (Flu-Pro)', Value in Health, 19, pp. A220 - A221, http://dx.doi.org/10.1016/j.jval.2016.03.1186
, 2016, 'Oral abstracts of the 21st International AIDS Conference 18-22 July 2016, Durban, South Africa.', J Int AIDS Soc, 19, pp. 21264, http://dx.doi.org/10.7448/IAS.19.6.21264
Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus J; Wentworth D; Johnson M; Vjecha MJ; Kelleher AD; Emery S; Aagaard B; Aragon E; Arnaiz J; Borup L; Clotet B; Dragsted U; Fau A; Gey D; Grarup J; Hengge U; Herrero P; Jansson P; Jensen B; Jensen K; Juncher H; Lopez P; Lundgren JD; Matthews C; Mollerup D; Pearson M; Phillips A; Reilev S; Tillmann K; Varea S; Angus B; Babiker A; Cordwell B; Darbyshire J; Dodds W; Fleck S; Horton J; Hudson F; Moraes Y; Pacciarini F; Palfreeman A; Paton N; Smith N; Van Hooff F; Bebchuk J; Collins G; Denning E; DuChene A; Fosdick L; Harrison M; Herman-Lamin K; Krum E; Larson G; Neaton J; Nelson R; Quan K; Quan S; Schultz T; Thompson G; Wyman N; Carey C; Chan F; Cooper D; Courtney-Rodgers D; Drummond F; Harrod M; Jacoby S; Kearney L; Lin E; Pett S; Robson R; Seneviratne N; Stewart M; Watts E; Finley E; Gordin F; Sánchez A; Standridge B; Belloso W; Davey R; Duprez D; Gatell J; Hoy J; Lifson A; Pederson C; Perez G; Price R; Prineas R; Rhame F; Sampson J; Worley J; Modlin J; Beral V; Chaisson R; Fleming T; Hill C; Bloch M; Cooper D; Konecny P; Carr A; Medland N; Sullivan J; Han A, 2015, 'Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study', PLoS ONE, 10, pp. e0139981, http://dx.doi.org/10.1371/journal.pone.0139981
Borges ÁH; O'Connor JL; Phillips AN; Rönsholt FF; Pett S; Vjecha MJ; French MA; Lundgren JD, 2015, 'Factors Associated with Plasma IL-6 Levels during HIV Infection', Journal of Infectious Diseases, 212, pp. 585 - 595, http://dx.doi.org/10.1093/infdis/jiv123
Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Nwizu C; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Avihingsanon A; Boyd M; Carey D; Clarke A; Courtney-Vega K; Delfino M; Donaldson A; Emery S; Espinosa N; Johannesen T; Lin E; Losso M; Moricz A; Pett S; Phanupak P; Puls R; Pussadee K; Sutheerasak P; Tomlins L; Ubolyam S; bin Raja Azwa RIS; Bissio E; Calanni L; Chetchotisakd P; Doong N; Elliott J; Gazzard B; Kelly M; Laplume H; del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Phanuphak P; Rockstroh J; Rowling D; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Dunn D; Dolan M; Emery S; Kelleher A, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5
Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD; Agan BK; Alston-Smith B; Arenas-Pinto A; Arribas JR; Baker JV; Baxter J; Belloso WH; Brekke K; Brew B; Brobst SW; Burman W; Carey C; Clark R; Cooper DA; Davey RT; De La Rosa G; Denning ET; Dolan M; Dore G; Duprez D; Emanuel E; Grady C; Grund B; Hirschel B; Hoen B; Hudson F; Johnson MA; Kambili C; Klingman K; Kunisaki KM; Landay A; Ledergerber B; Lehrman SN; Martinez A; Meger S; Misar K; Mitsuyasu RT; Mocroft A; Munroe D; Norton M; Palmer RC; Pett SL; Phillips A; Pillay D; Porter D; Price RW; Proschan M; Rappoport C; Reiss P; Renjifo B; Robertson K; Rockstroh J; Rodriguez G; Rooney JF; Ross MJ; Schechter M; Schwarze S; Seekins D; Sharma S; Snowden W; Telenti A; Tryon J; van Wyk J; Vjecha MJ; Wright E; Cooper D, 2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, 16, pp. 1 - 9, http://dx.doi.org/10.1111/hiv.12227
Mocroft A; Lundgren JD; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Neuhaus J; Fux CA; Moranne O; Morlat P; Johnson MA; Ryom L; Powderly B; Shortman N; Moecklinghoff C; Reilly G; Franquet X; Sabin CA; Phillips A; Weber R; Pradier C; d'Arminio Monforte A; Dabis F; El-Sadr WM; De Wit S; Kamara D; Tverland J; Mansfeld M; Nielsen J; Raben D; Salbøl Brandt R; Rickenbach M; Fanti I; Krum E; Hillebregt M; Geffard S; Sundström A; Delforge M; Fontas E; Torres F; McManus H; Wright S; Kjær J; Sjøl A; Meidahl P; Helweg-Larsen J; Schmidt Iversen J; Kesselring AM; Friis-Møller N; Kowalska J; Sabin C; Bruyand M; Bower M; Fätkenheuer G; Donald A; Grulich A; Prins JM; Kuijpers TW; Scherpbier HJ; van der Meer JTM; Wit FWMN; Godfried MH; van der Poll T; Nellen FJB; Geerlings SE; van Vugt M; Pajkrt D; Bos JC; Wiersinga WJ; van der Valk M; Goorhuis A; Hovius JW; van Eden J; Henderiks A; van Hes AMH; Mutschelknauss M; Nobel HE; Pijnappel FJJ; Westerman AM; Jurriaans S; Back NKT; Zaaijer HL; Berkhout B; Cornelissen MTE; Schinkel CJ; Thomas XV; van den Berge M; Stegeman A; Baas S; Hage de Looff L; Versteeg D; Pronk MJH; Ammerlaan HSM; Korsten-Vorstermans EMHM; de Munnik ES; Jansz AR; Tjhie J; Finlayson R; Cooper D; Carr A; Bloch M; Harrod M; Pett S; Petoumenos K; Gold J; Medland N; Sullivan J; Han A, 2015, 'Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study', PLoS Medicine, 12, pp. e1001809, http://dx.doi.org/10.1371/journal.pmed.1001809
Madhavi V; Ana-Sosa-Batiz FE; Jegaskanda S; Center RJ; Winnall WR; Parsons MS; Ananworanich J; Cooper DA; Kelleher AD; Hsu D; Pett S; Stratov I; Kramski M; Kent SJ, 2015, 'Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy', Journal of Infectious Diseases, 211, pp. 529 - 538, http://dx.doi.org/10.1093/infdis/jiu486
Baker JV; Engen NW; Huppler Hullsiek K; Stephan C; Jain MK; Munderi P; Pett S; Duprez D; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group , 2015, 'Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.', HIV Med, 16 Suppl 1, pp. 109 - 118, http://dx.doi.org/10.1111/hiv.12239
Jackson Y; Pinto A; Pett S, 2014, 'Chagas disease in Australia and New Zealand: Risks and needs for public health interventions', Tropical Medicine and International Health, 19, pp. 212 - 218, http://dx.doi.org/10.1111/tmi.12235
Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Emery S; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Losso M; Nwizu C; Phanuphak P; Ripin D; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Boyd M; Carey D; Clarke A; Courtney-Vega K; Dazo C; Delfino M; Donaldson A; Espinosa N; Johannesen T; Kaew-On P; Lin E; Moricz A; Taylor J; Phanupak P; Puls RL; Pussadee K; Sutheerasak P; Tomkins L; Ubolyam S; Shah Bin Raja Azwa RI; Bissio E; Calanni L; Casiro A; Chetchotisakd P; Contarelli J; Doong N; Elliott J; Gazzard B; Kelly M; Del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Pett S; Rockstroh J; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Crabtree-Ramiraz B; Winston E; Dunn D; Dolan M; Cooper D; Kelleher A, 2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial', The Lancet, 383, pp. 1474 - 1482, http://dx.doi.org/10.1016/S0140-6736(13)62187-X
Back to profile page